Influence of co-medicated drugs on the biotransformation of ThioTEPA to TEPA and ThioTEPA-mercapturate

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1711-1716

  Van Maanen, M J ^a,b   Huitema, A D R ^b   Beijen, J H ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Biotransformation; Enzyme kinetics; Glutathione conjugation; ThioTEPA

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; ACICLOVIR; AMPHOTERICIN B; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUCONAZOLE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GRANISETRON; ITRACONAZOLE; LORAZEPAM; ONDANSETRON; RANITIDINE; TEPA; THIOTEPA;

ARTICLE; BIOTRANSFORMATION; DRUG INHIBITION; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; MICROSOME; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GLUTATHIONE; HUMANS; KINETICS; MICROSOMES; THIOTEPA; TRIETHYLENEPHOSPHORAMIDE;

EID: 0033859927     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Van der Wall E, Beijnen JH and Rodenhuis S: High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 21: 105-132, 1995.
2. Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connaghan DG, Hillyer CD, Hughes LL and Miller RL et al: Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thioTEPA, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 14: 1156-1164, 1996.
3. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, Van der Wall E, Slaper-Cortenbach ICM and Schornael JH: Feasibility of mutliple courses of high-dose cyclophosphamide, thioTEPA and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14: 1473-1483, 1996.
4. Mellet LB and Woods LA: The comparative physiological disposition of thioTEPA and TEPA in the dog. Cancer Res 20: 524-532, 1960.
5. Chang TKH, Chen G and Waxman DJ: Modulation of thioTEPA antitumor-activity in-vivo by alteration of liver cytochrome P450-catalyzed drug-metabolism. J Pharmacol Exp Ther 274: 270-275, 1995.
6. Ng SF and Waxman DJ: Biotransformation of N, N′, N″-Triethylenethiophosphoramide: oxidative desulfuration to yield N, N′, N″-Triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res 50: 464-471, 1990.
7. Sykes M, Karnovsky D, Phillips F and Burchenal J: Clinical studies of triethylenephosphoramide and diethylenephosphoramide compounds with nitrogen mustard-like activity. Cancer 6: 142-148, 1953.
8. Maanen MJ van, Tijhof IM, Damen JMA, Versluis C, Kettenes-Van den bosch JJ, Heck AJR, Rodenhuis S and Beijnen JH: A search for new metabolites of N, N′, N″-Triethylenethiophosphoramide. Cancer Res 59: 4720-4724, 1999.
9. Gibson GG and Skett P: Introduction to drug metabolism. London, Chapman and Hall, 1986.
10. Chasseaud LF: Conjugation with glutathione and mercapturic acid excretion. In: Glutathione: Metabolism anf function (Arias IM and Jakoby WB, eds). New York, Raven Press, pp 77-114, 1976.
11. Dirven HAAM, Dictus ELJT, Broeders NLHL, Vanommen B and Bladeren PJ: The role of human glutathione-S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thioTEPA. Cancer Res 55: 1701-1706, 1995.
12. Cnubben NHP, Rommens AJM, Oudshoorn MJ and Bladeren PJ van: Glutathione-dependent biotransformation of the alkylating drug thioTEPA and transport of its metabolite monoglutathionylthioTEPA in human MCF-7 breast cancer cells. Cancer Res 58: 4616-4623, 1998.
13. Moore MJ: Clinical Pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 144-208, 1991.
14. Ren S, Yang JS and Slattery JT: Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 47: 4229-4235, 1997.
15. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG and Clark B: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692-1703, 1991.
16. Chen TL, Passoscoelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM and Grochow LB: Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast-cancer receiving high-dose chemotherapy followed by autologous bone-marrow transplantation. Cancer Res 55: 810-816, 1995.
17. Anderson LW, Chen T, Colvin OM, Grochow LB, Collins JM, Kennedy MJ and Strong JM: Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2: 1481-1487, 1996.
18. Przepiorka D, Madden T, Ippoliti C, Estrov Z and Dimopoulos M: Dosing of thioTEPA for myeloablative therapy. Cancer Chemother Pharmacol 37: 155-160, 1995.
19. Lazarus HM, Reed MD, Spitzer TR, Rabas MS and Blumer JL: High-dose i.v. thioTEPA and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71: 689-695, 1987.
20. Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA and Bitran JD: Human plasma pharmacokinetics of thioTEPA following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol 6: 1192-1196, 1988.
21. Tantcheva LP, Rangelova DS and Stoytchev TzS: Effects of acetysal, dexamethasone and their combination on drug metabolizing enzyme systems in rat microsomes. Eur J Drug Metab Pharmacokinet 20: 281-286, 1995.
22. Schulz TG, Stahlmann R, Edwards RJ, Debri K, Davies DS and Neubert D: Enoxacin is an inducer of CYP12 in rat liver. Biochem Pharmacol 50: 1517-1520, 1995.
23. Kantola T, Kivisto KT and Neuvonen PJ: Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54: 851-855, 1999.
24. Kunze KL, Wienkers LC, Thummel KE and Traer WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24: 414-421, 1996.
25. Maanen RJ van, Oojen RD van, Zwikker JW, Huitema ADR, Rodenhuis S and Beijnen JH: Determination of N, N′, N″-Triethylenethiophosphoramide and its active metabolite N, N′, N″-Triethylenephosphoramide in plasma and urine using capillary gas chromatography. J Chromatogr B 719: 103-112, 1998.
26. Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Sotomayor EA, Jones SM and Frei III E: Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N, N′, N″-Triethylenethiophosphoramide. Cancer Res 49: 4996-5001, 1989.
27. Parker AC, Preston T, Heaf D, Kitteringham NR and Choonara I: Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine reath test. Br J Clin Pharmac 38: 573-576, 1994.
28. Gentile DM, Tomlinson ES, Maggs JL, Park BK and Back DJ: Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277: 105-112, 1996.
29. Bloomer JC, Baldwin Sj, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ: Characterisation of the cytochrome p450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmac 38: 557-566, 1994.
30. Waxman DJ: Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy - A review. Cancer Res 50: 6449-6454, 1990.
31. Mattern J and Volm M: Multiple pathway of drug resistance (review).Int J Oncol 2: 557-561, 1993.
32. Yuan Z, Smith PB, Brundrett RB, Colvin M and Fenselau C: Glutathione conjugation with phosphoramide mustard and cyclophosphamide - A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 19: 625-629, 1991.
33. Dirven HAAM, Ommen B van and Bladeren PJ van: Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54:6215-6220, 1994.